GLA and myasthenia gravis: Two OS publications of MG populations reported no change in LVEF when patients were switched from agalsidase beta 1.0 mg/kg to agalsidase alfa 0.2 mg/kg EOW (105 patients followed for 8–16 months [181] and ten patients followed for 20 months [179]).